Business Wire

HCL Technologies Launches X to Power World-Class Digital Engagement for Global Consumer Brands

31.5.2022 14:19:00 EEST | Business Wire | Press release

Share

HCL Technologies (HCL), a leading global technology company, has launched a world-class digital engagement platform, X by HCL Technologies (X), which enables brands to improve consumer loyalty and drive conversions through personalized omnichannel marketing. Research shows only 13% of organizations have a seamlessly integrated marketing and technology stack and brands rely on many different data sources to unlock customer insights. HCL Technologies’ X overcomes these challenges by uniting multiple digital touchpoints, including websites, mobile apps and social media feeds, to create a single view of the consumer. This helps marketers access data-driven insights that enable them to optimize the customer experience and unlock the potential of their brand.

Initially created to underpin Manchester United’s rapidly expanding digital engagement channels, the award-winning platform is now available to help other global brands drive their own success stories by delivering personalized, timely communications and content. Manchester United’s global fanbase has grown with X and the club has experienced a twofold increase in digital engagement with consumers via its website.

Key features and capabilities of the platform include:

  • Publishing: Multilingual content delivery, rich media management, real-time notifications and communication, automated publishing across devices and social channels and audience search and recommendations help brands increase consumer loyalty, through contextual and localized content.
  • Engagement: Brands can activate complex, targeted and personalized campaigns in multiple languages to engage and retain consumer audiences, including gamification through polls and quizzes, loyalty and rewards scheme enablement, social engagement, relationship-building and livestreaming.
  • Conversion: A 360-degree view of the consumer, reduced campaign fragmentation, automated analytics into purchase behavior, measurable KPIs, promotion management and e-commerce integration capabilities enable brands to provide a seamless user experience throughout the customer journey.

“HCL Technologies’ X is a one-stop digital engagement and publishing platform for one of the world’s biggest sports brands and we’re excited to make it available to the wider market,” said Ashish Kumar Gupta, Chief Growth Officer, Europe and Africa, Diversified Industries, HCL Technologies. “The core purpose of X is to create the two-way, in-the-moment engagement that amplifies consumers’ connection with brands and converts users into advocates. Over the last four years, Manchester United’s experience has proven the significant rewards available to organizations that can harness X to drive world-class digital engagement. We look forward to enabling other marketers to use the next-generation capabilities of our platform to improve brand loyalty and optimize revenue growth.”

“The ability to create a two-way digital dialogue with our fans is vital to scaling our brand to a wider global audience,” said Phil Lynch, Chief Executive Officer of Media, Manchester United. “The platform HCL built for us has proven to be the perfect foundation to enable continued growth by providing the insights the club and its partners need to deliver meaningful and personalized content that truly engages our fans. The capabilities the platform provides will ensure we are well-equipped to continue creating compelling brand experiences for our fans long into the future.”

"Anglo American is committed to driving sustainable change for the communities that host us,” said Zaheera Soomar, Global Head of Education, Anglo American. “As part of that goal, we want to ensure all children in our host communities have access to excellent education and training opportunities to reach their true potential. X by HCL Technologies is enabling us to deliver on that promise by creating a world-class student and teacher engagement platform for early years, primary, secondary and post-secondary education in South Africa. This platform has been purpose-built to support students from communities with limited internet connectivity, providing access to more than 2,000 zero-rated and subsidized learning materials and resources. X also enables us to establish a two-way dialogue with those students, bringing us closer to our communities and enabling us to support their education and skills journeys better."

“Digital experiences today are multisensory and context-aware. IDC research finds more than 46% of organizations place customer experience programs as a strategic priority to ensure the business' long-term success. Ultimately, they realize the importance of content in delivering a multi-channel interactive relationship with the consumer,” said Marci Maddox, Research Director, Digital Experience Strategies at IDC. “Traditional approaches to content publishing are becoming obsolete as modern engagement platforms offer organizations multiple entry points into strengthening the relationship with their customers and leveraging technology to automate and personalize digital experiences at scale.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further details, please contact:
HCL Technologies

Meenakshi Benjwal, Americas
meenakshi.benjwal@hcl.com

Elka Ghudial, EMEA
elka.ghudial@hcl.com

Devneeta Pahuja, India and APAC
devneeta.p@hcl.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye